• Aviv Clinics in Dubai is the only service of its kind in the GCC and MENA region that uses innovative hyperbaric oxygen therapy to help reverse some of the biological effects of ageing 

Dubai, UAE: Aviv Clinics is the only medical centre in the Middle East offering an advanced program to treat age related cognitive and physical decline to clients from the region, with hyperbaric oxygen therapy (HBOT) at its core. Looking to improve cognitive abilities, the Aviv Medical Program will help counter the effects of ageing, allowing clients to increase their vitality to perform their best, in body and mind.

Research has recently found that some countries in the Gulf such as UAE, Saudi Arabia, Kuwait and Qatar can anticipate a significant increase up to fivefold in their older population and according to the World Health Organisation, the shift in these countries’ population demographics  can result in an increase in the possible number of people who may be susceptible to developing Alzheimer’s disease, estimating that from 2000 to 2050, Alzheimer’s amount the elderly is set to rise by 4 to 5 percent.

There are various factors that will continue to play a role in increasing these numbers, especially in the GCC. This includes the youth population’s migration to other countries, for employment or for a better education, which ultimately creates gaps between family members.

Research by the Healthcare and Life Sciences Transaction Advisory Services states that the heaviest users of healthcare – the elderly – are becoming an ever-larger portion of the GCC population. Many estimates suggest that the population above 65 is set to more than double through 2050, as people live longer.

GCC nationals are a key part of the population segment, having played pivotal roles in the development of the region, and being key anchors for most families.

When it comes to the working age population, the research also believes that both GCC nationals and non-nationals appear likely to encounter more severe health problems as a result of many years of living with advancing chronic diseases.

Conditions such as dementia and Alzheimer’s have significant social and economic implications in terms of direct medical and social care costs (more than $1.3 trillion globally), placing a huge economic strain on countries, some of which are already facing global health crises.

In response, Aviv has developed its pioneering medical program with a unique protocol of Hyperbaric Oxygen therapy (HBOT) at its core – a non-pharmaceutical, non-invasive method that involves administering patients with a hundred per cent pure oxygen in a pressurised environment to accelerate normal organ function and tissue repair. The program also includes a series of comprehensive assessments to holistically evaluate a patient’s health, a personalised cognitive training plan, a fitness plan and nutrition coaching – all together aiming to enhance the patient’s performance and improve their capabilities and quality of life.

Studies by Sagol School of Neuroscience in Tel Aviv and Tel Aviv University have shown that this unique HBOT protocol has proven effective in reversing the main activators and early symptoms of Alzheimer’s disease. 

By using its innovative methods to help reverse the main activators behind developing early symptoms of Alzheimer’s and dementia, and treat brain and cognitive problems such as memory loss, the UAE-based company will further strengthen Dubai’s position as an innovative medical hub for the region.

Aviv Clinics has also recently published a landmark study that proves - for the first time; the effectiveness of using a unique protocol of Hyperbaric Oxygen Therapy (HBOT) in reversing early indicators that could lead to the development of Alzheimer’s disease. The study also revealed that hyperbaric oxygen treatment, led to improvement in the blood flow, blood vessels and as a result increase the performance of the brain and body functionality of elderly patients such as stronger focus and memory retention, increased energy and stamina, as well as a strengthened immune system, amongst countless other benefits.

Dr. Efrati, Director of the world-leading Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Chair of Aviv’s Medical Advisory Board said: “Age should never be a factor in determining how mentally or physically fit a person is. HBOT can be used as a viable drug-free and non-invasive solution to treat the decline in age related cognitive and physical performance, and we are pleased to be able to offer our unique program to patients in the UAE and across the region access to our breakthrough medical treatment right here at our clinic in the heart of Dubai.”


Aviv Clinics

Aviv Clinics is the leader in the research and treatment of age-related cognitive and functional decline and novel applications of hyperbaric oxygen therapy (HBOT) to maximize human performance. Based on an exclusive partnership with the world’s largest hyperbaric medicine and research facility, the Sagol Center at Shamir Medical Center in Israel, Aviv is introducing a global network of clinics delivering the most effective evidence-based treatment of the aging process – the Aviv Medical Program. The three-month regimen designed to improve the aging process in healthy adults was developed on over a decade of research and more than 1,000 patients treated worldwide under the scientific leadership of Shai Efrati, M.D., Chair of Aviv Scientific’s Medical Advisory Board and Director of the Sagol Center.

For more information, please contact:
Hiba Eid
+971 50 5095 306

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.